TCT-764 Safety and Biocompatibility of the Coherex WaveCrest™ Left Atrial Appendage Occluder in a 30-Day Canine Study

Left atrial appendage (LAA) occlusion is proposed to reduce the risk of thromboembolic stroke in atrial fibrillation patients. WaveCrest™ (Coherex Medical, Salt Lake City, UT) LAA occluder was deployed in 6 dogs via transseptal puncture under fluoroscopy and transesophageal echocardiography (TEE